Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Khoo, T; Gao, Lan

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

journal contribution

posted on 2024-06-06, 10:34 authored by T Khoo, Lan GaoLan Gao

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

History

Journal

Expert Review of Pharmacoeconomics and Outcomes Research

Volume

21

Pagination

415-423

Location

England

ISSN

1473-7167

eISSN

1744-8379

Language

English

Author URL

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596294300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

C1 Refereed article in a scholarly journal

Issue

3

Publisher

TAYLOR & FRANCIS LTD

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Health Care Sciences & Services Health Policy & Services Pharmacology & Pharmacy Osimertinib non-small cell lung cancer EGFR mutation economic evaluation cost-effectiveness 3214 Pharmacology and pharmaceutical sciences 3211 Oncology and carcinogenesis

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

History

Journal

Volume

Pagination

Location

ISSN

eISSN

Language

Author URL

Publication classification

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports